Pasar al contenido principal

ESTRATEGIAS EMERGENTES PARA ENFERMEDADES SIN TRATAMIENTO EFICAZ

PID2019-106279RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

A new fluorescent probe for the visualization of progerin

  • Macicior Michelena, Jon
  • Fernández, Daniel
  • Ortega Gutiérrez, Silvia
Hutchinson-Gilford progeria syndrome (HGPS) or progeria is a rare genetic disease that causes premature aging, leading to a drastic reduction in the life expectancy of patients. Progeria is mainly caused by the intracellular accumulation of a defective protein called progerin, generated from a mutation in the LMNA gene. Currently, there is only one approved drug for the treatment of progeria, which has limited efficacy. It is believed that progerin levels are the most important biomarker related to the severity of the disease. However, there is a lack of effective tools to directly visualize progerin in the native cellular models, since the commercially available antibodies are not well suited for the direct visualization of progerin in cells from the mouse model of the disease. In this context, an alternative option for the visualization of a protein relies on the use of fluorescent chemical probes, molecules with affinity and specificity towards a protein. In this work we report the synthesis and characterization of a new fluorescent probe (UCM-23079) that allows for the direct visualization of progerin in cells from the most widely used progeroid mouse model. Thus, UCM-23079 is a new tool compound that could help prioritize potential preclinical therapies towards the final goal of finding a definitive cure for progeria.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Discovery of V-0219: a small-molecule positive allosteric modulator of the Glucagon-Like Peptide-1 Receptor toward oral treatment for “diabesity”

  • Decara del Olmo, Juan Manuel
  • Vázquez Villa, Henar
  • Brea Floriani, José Manuel
  • Alonso, Mónica
  • Srivastava, Raj Kamal
  • Orio Ortiz, Laura
  • Alén Fariñas, Francisco
  • Suárez Pérez, Juan
  • Baixeras Llano, Elena
  • García Cárceles, Javier
  • Escobar Peña, Andrea
  • Lutz, Beat
  • Rodríguez, Ramón
  • Codesido, Eva
  • Garcia Ladona, F. Javier
  • Bennett, Teresa A.
  • Ballesteros, Juan A.
  • Cruces, Jacobo
  • Loza García, María Isabel
  • Benhamú Salama, Bellinda
  • Rodríguez de Fonseca, Fernando
  • López Rodríguez, María L.
Peptidic agonists of the glucagon-like peptide-1 receptor (GLP-1R) have gained a prominent role in the therapy of type-2 diabetes and are being considered for reducing food intake in obesity. Potential advantages of small molecules acting as positive allosteric modulators (PAMs) of GLP-1R, including oral administration and reduced unwanted effects, could improve the utility of this class of drugs. Here, we describe the discovery of compound 9 (4-{[1-({3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)piperidin-3-yl]methyl}morpholine, V-0219) that exhibits enhanced efficacy of GLP-1R stimulation, subnanomolar potency in the potentiation of insulin secretion, and no significant off-target activities. The identified GLP-1R PAM shows a remarkable in vivo activity, reducing food intake and improving glucose handling in normal and diabetic rodents. Enantioselective synthesis revealed oral efficacy for (S)-9 in animal models. Compound 9 behavior bolsters the interest of a small-molecule PAM of GLP-1R as a promising therapeutic approach for the increasingly prevalent obesity-associated diabetes
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting the FtsZ allosteric binding site with a novel fluorescence polarization screen, cytological and structural approaches for antibacterial discovery

  • Huecas, Sonia
  • Araújo-Bazán, Lidia
  • Ruiz, Federico M.
  • Ruiz-Avila, Laura B.
  • Martínez, R. Fernando
  • Escobar-Peña, Andrea
  • Artola, Marta
  • Vazquez-Villa, Henar
  • Martín-Fontecha, Mar
  • Fernández-Tornero, Carlos
  • Lopez-Rodriguez, M.L.
  • Andreu, José Manuel
51 p.-6 fig.-1 tab.-4 schem.-1 graph. abst., Bacterial resistance to antibiotics makes previously manageable infections again disabling and lethal, highlighting the need for new antibacterial strategies. In this regard, inhibition of the bacterial division process by targeting key protein FtsZ has been recognized as an attractive approach for discovering new antibiotics. Binding of small molecules to the cleft between the N-terminal guanosine triphosphate (GTP)-binding and the C-terminal subdomains allosterically impairs the FtsZ function, eventually inhibiting bacterial division. Nonetheless, the lack of appropriate chemical tools to develop a binding screen against this site has hampered the discovery of FtsZ antibacterial inhibitors. Herein, we describe the first competitive binding assay to identify FtsZ allosteric ligands interacting with the interdomain cleft, based on the use of specific high-affinity fluorescent probes. This novel assay, together with phenotypic profiling and X-ray crystallographic insights, enables the identification and characterization of FtsZ inhibitors of bacterial division aiming at the discovery of more effective antibacterials., Thiswork was supported by grants BFU 2014-51823-R (J.M.A.),SAF2016-78792-R, PID2019-106279RB-I00 (M.L.L.-R.), BFU2017-87387-P (C.F.-T.), and predoctoral FPU fellowshipsfrom MECD (A.E.-P. and M.A.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The search for antibacterial inhibitors targeting cell division protein FtsZ at its nucleotide and allosteric binding sites

  • Andreu, José Manuel
  • Huecas, Sonia
  • Araújo-Bazán, Lidia
  • Vazquez-Villa, Henar
  • Martin-Fontecha, M.
18 p.-7 fig., The global spread of bacterial antimicrobial resistance is associated to millions of deaths from bacterial infections per year, many of which were previously treatable. This, combined with slow antibiotic deployment, has created an urgent need for developing new antibiotics. A still clinically unexploited mode of action consists in suppressing bacterial cell division. FtsZ, an assembling GTPase, is the key protein organizing division in most bacteria and an attractive target for antibiotic discovery. Nevertheless, developing effective antibacterial inhibitors targeting FtsZ has proven challenging. Here we review our decade-long multidisciplinary research on small molecule inhibitors of bacterial division, in the context of global efforts to discover FtsZ-targeting antibiotics. We focus on methods to characterize synthetic inhibitors that either replace bound GTP from the FtsZ nucleotide binding pocket conserved across diverse bacteria or selectively bind into the allosteric site at the interdomain cleft of FtsZ from Bacillus subtilis and the pathogen Staphylococcus aureus. These approaches include phenotype screening combined with fluorescence polarization screens for ligands binding into each site, followed by detailed cytological profiling, and biochemical and structural studies. The results are analyzed to design an optimized workflow to identify effective FtsZ inhibitors, and new approaches for the discovery of FtsZ-targeting antibiotics are discussed., Research in our laboratories was funded in part by the Ministerio de Ciencia e Innovación, grants BFU 2014-51823-R (JMA, SH, LAB) and PID2019-106279RB-I00 (HVV, MMF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota-Inspired Synthetic Compound Targeting NPM1 for Leukemia

  • Algar, Sergio
  • Vázquez-Villa, Henar
  • Aguilar-Garrido, Pedro
  • Navarro-Aguadero, Miguel Ángel
  • Velasco-Estévez, María
  • Sánchez-Merino, Anabel
  • Arribas-Álvarez, Iván
  • Paradela, Alberto
  • Giner-Arroyo, Rafael L.
  • Tamargo-Azpilicueta, Joaquín
  • Díaz-Moreno, Irene
  • Martínez-López, Joaquín
  • Gallardo, Miguel E.
  • López-Rodríguez, María Luz
  • Benhamú, Bellinda
Topic name Nuclear Protein; Nucleophosmin; Tumor Suppressor Protein Prominence percentile 67.656, The human microbiota plays an important role in human health and disease, through the secretion of metabolites that regulate key biological functions. We propose that microbiota metabolites represent an unexplored chemical space of small drug-like molecules in the search of new hits for drug discovery. Here, we describe the generation of a set of complex chemotypes inspired on selected microbiota metabolites, which have been synthesized using asymmetric organocatalytic reactions. Following a primary screening in CSC models, we identified the novel compound UCM-13369 (4b) whose cytotoxicity was mediated by NPM1. This protein is one of the most frequent mutations of AML, and NPM1-mutated AML is recognized by the WHO as a distinct hematopoietic malignancy. UCM-13369 inhibits NPM1 expression, downregulates the pathway associated with mutant NPM1 C+, and specifically recognizes the C-end DNA-binding domain of NPM1 C+, avoiding the nucleus-cytoplasm translocation involved in the AML tumorological process. The new NPM1 inhibitor triggers apoptosis in AML cell lines and primary cells from AML patients and reduces tumor infiltration in a mouse model of AML with NPM1 C+ mutation. The disclosed phenotype-guided discovery of UCM-13369, a novel small molecule inspired on microbiota metabolites, confirms that CSC death induced by NPM1 inhibition represents a promising therapeutic opportunity for NPM1-mutated AML, a high-mortality disease., This work was supported by grants PID2022-138797OB-I00, PGC2018-096049-B-I00 and PID2021-126663NB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; grant PID2019-106279RB-I00 funded by MCIN/AEI/10.13039/501100011033; grant PDC2022-133488-I00 funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”; grants PI21/00191 and CP19/00140 funded by Instituto de Salud Carlos III; CNIO agreements 2017-2020, 2020-2023 funded by Foundation CRIS contra el Cancer; grants BIO-198 and P18-FR-3487 funded by Junta de Andalucía; VI PPIT program funded by Universidad de Sevilla; and by Ramón Areces Foundation. The authors acknowledge technological support from NMR, mass spectrometry and elemental analysis CAIs (Complutense University of Madrid), Biointeractomicts Platform (cicCartuja, Seville), and the Services at CITIUS (University of Seville). S.A., A.S.-M., I.A.-A. and R.L.G.-A. are grateful to Ministerio de Ciencia e Innovación and Complutense University of Madrid for predoctoral fellowships; M.V.-E. to European Union’s Horizon 2020 for Marie Sklodowska-Curie grant; and P.A.-G. to Fundación Española de Hematología y Hemoterapia for grant. The authors thank Dr. Adrián Velázquez-Campoy at the University of Saragossa for helping in fitting ITC analysis and Prof. Miguel A. De la Rosa at the University of Seville for critical reading of the manuscript., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery

  • Huecas, Sonia
  • Araujo Bazán, Lidia
  • Ruiz, Federico
  • Ruiz Ávila, Laura
  • Martínez, R. Fernando
  • Escobar Peña, Ana Andrea
  • Artola, Marta
  • Vázquez Villa, María Del Henar
  • Martín-Fontecha Corrales, María Del Mar
  • Fernández Tornero, Carlos
  • López Rodríguez, María Luz
  • Andreu, José M.
Bacterial resistance to antibiotics makes previously manageable infections again disabling and lethal, highlighting the need for new antibacterial strategies. In this regard, inhibition of the bacterial division process by targeting key protein FtsZ has been recognized as an attractive approach for discovering new antibiotics. Binding of small molecules to the cleft between the N-terminal guanosine triphosphate (GTP)-binding and the C-terminal subdomains allosterically impairs the FtsZ function, eventually inhibiting bacterial division. Nonetheless, the lack of appropriate chemical tools to develop a binding screen against this site has hampered the discovery of FtsZ antibacterial inhibitors. Herein, we describe the first competitive binding assay to identify FtsZ allosteric ligands interacting with the interdomain cleft, based on the use of specific high-affinity fluorescent probes. This novel assay, together with phenotypic profiling and X-ray crystallographic insights, enables the identification and characterization of FtsZ inhibitors of bacterial division aiming at the discovery of more effective antibacterials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel antagonist of the type 2 lysophosphatidic acid receptor (LPA), UCM-14216, ameliorates spinal cord injury in mice

  • Khiar-Fernández, Nora
  • Zian, Debora
  • Vázquez-Villa, Henar|||0000-0001-7911-3160
  • Martínez, R. Fernando|||0000-0002-3278-6074
  • Escobar-Peña, Andrea
  • Foronda-Sainz, Román
  • Ray, Manisha
  • Puigdomenech Poch, Maria
  • Cincilla, Giovanni|||0000-0002-5242-0707
  • Sánchez-Martínez, Melchor|||0000-0002-3674-8577
  • Kihara, Yasuyuki
  • Chun, Jerold
  • López Vales, Rubén|||0000-0001-7615-9550
  • López-Rodríguez, María L.|||0000-0001-8607-1085
  • Ortega-Gutiérrez, Silvia|||0000-0002-0257-6754
Spinal cord injuries (SCIs) irreversibly disrupt spinal connectivity, leading to permanent neurological disabilities. Current medical treatments for reducing the secondary damage that follows the initial injury are limited to surgical decompression and anti-inflammatory drugs, so there is a pressing need for new therapeutic strategies. Inhibition of the type 2 lysophosphatidic acid receptor (LPA) has recently emerged as a new potential pharmacological approach to decrease SCI-associated damage. Toward validating this receptor as a target in SCI, we have developed a new series of LPA antagonists, among which compound 54 (UCM-14216) stands out as a potent and selective LPA receptor antagonist (E = 90%, IC = 1.9 μM, K = 1.3 nM; inactive at LPA receptors). This compound shows efficacy in an in vivo mouse model of SCI in an LPA-dependent manner, confirming the potential of LPA inhibition for providing a new alternative for treating SCI.